全文获取类型
收费全文 | 6067篇 |
免费 | 311篇 |
国内免费 | 155篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 22篇 |
妇产科学 | 21篇 |
基础医学 | 198篇 |
口腔科学 | 29篇 |
临床医学 | 123篇 |
内科学 | 313篇 |
皮肤病学 | 8篇 |
神经病学 | 139篇 |
特种医学 | 68篇 |
外科学 | 114篇 |
综合类 | 659篇 |
预防医学 | 97篇 |
眼科学 | 31篇 |
药学 | 3851篇 |
4篇 | |
中国医学 | 826篇 |
肿瘤学 | 16篇 |
出版年
2024年 | 74篇 |
2023年 | 158篇 |
2022年 | 200篇 |
2021年 | 257篇 |
2020年 | 236篇 |
2019年 | 367篇 |
2018年 | 352篇 |
2017年 | 282篇 |
2016年 | 304篇 |
2015年 | 230篇 |
2014年 | 414篇 |
2013年 | 440篇 |
2012年 | 324篇 |
2011年 | 389篇 |
2010年 | 314篇 |
2009年 | 257篇 |
2008年 | 280篇 |
2007年 | 230篇 |
2006年 | 209篇 |
2005年 | 149篇 |
2004年 | 145篇 |
2003年 | 125篇 |
2002年 | 95篇 |
2001年 | 91篇 |
2000年 | 75篇 |
1999年 | 40篇 |
1998年 | 33篇 |
1997年 | 30篇 |
1996年 | 43篇 |
1995年 | 39篇 |
1994年 | 27篇 |
1993年 | 39篇 |
1992年 | 39篇 |
1991年 | 26篇 |
1990年 | 17篇 |
1989年 | 15篇 |
1988年 | 17篇 |
1987年 | 13篇 |
1986年 | 22篇 |
1985年 | 16篇 |
1984年 | 16篇 |
1982年 | 10篇 |
1981年 | 8篇 |
1980年 | 6篇 |
1976年 | 6篇 |
1975年 | 11篇 |
1974年 | 15篇 |
1973年 | 11篇 |
1972年 | 9篇 |
1971年 | 6篇 |
排序方式: 共有6533条查询结果,搜索用时 31 毫秒
1.
《Revista de gastroenterologia de Mexico》2022,87(1):52-58
IntroductionThe sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12 weeks post-treatment a relevant undertaking.MethodsA retrospective review of the case records of 241 patients seen at 20 hospitals in Mexico was conducted to assess hepatitis C treatment with the SOF/VEL combination (n = 231) and the sofosbuvir/velpatasvir/ribavirin (SOF/VEL/RBV) combination (n = 10). The primary efficacy endpoint was the percentage of patients that achieved SVR at 12 weeks after the end of treatment.ResultsOverall SVR was 98.8% (95% CI 97.35-100%). Only three patients did not achieve SVR, two of whom had cirrhosis and a history of previous treatment with peg-IFN. Of the subgroups analyzed, all the patients with HIV coinfection, three patients with genotype 3, and the patients treated with the SOF/VEL/RBV combination achieved SVR. The subgroups with the lower success rates were patients that were treatment-experienced (96.8%) and patients with F1 fibrosis (95.5%). The most frequent adverse events were fatigue, headache, and insomnia. No serious adverse events were reported.ConclusionTreatments with SOF/VEL and SOF/VEL/RBV were highly safe and effective, results coinciding with those of other international real-world studies. 相似文献
2.
目的:探索健脾生血片治疗慢性心力衰竭伴贫血的疗效、安全性和作用机制。方法:选取2016年5月至2017年2月同济医院收治的慢性心力衰竭贫血患者144例,按照随机数字表法分为观察组和对照组,每组72例。观察组给予健脾生血片治疗,3片/次,3次/d,疗程3个月;对照组给予生血宝合剂治疗,15 m L/次,3次/d,3个月为1个疗程。比较2组患者治疗前与治疗后血红蛋白、红细胞计数、网织红细胞、血清铁、转铁蛋白饱和度、血清铁蛋白、血清铁调素(Hepcidin)、血清IL-1β、血清肿瘤坏死因子-α(TNF-α)、血清C反应蛋白(CRP)、左室射血分数(LVEF)、6 min步行距离、明尼苏达心力衰竭生命质量量表(MLHFQ)和不良事件。并随访2组心血管事件次数,住院次数与全因死亡率。结果:观察组72例患者完成了前3个月的治疗,随访期间脱失2例;对照组治疗期间1例患者退出研究,随访期间脱失4例。2组一般资料比较,差异无统计学意义(P 0. 05),具有可比性。观察组贫血有效率98. 6%,对照组有效率11. 3%,差异有统计学意义(P0. 05)。治疗后观察组红细胞计数和网织红细胞、均显著高于对照组(P 0. 05)。观察组血清铁、转铁蛋白饱和度水平均高于对照组,差异有统计学意义(P 0. 05),但血清铁调素水平显著低于对照组,差异有统计学意义(P 0. 05),血清铁蛋白水平2组差异无统计学意义(P 0. 05)。观察组IL-1β、血清TNF-α、血清CRP均显著低于对照组,差异有统计学意义(P 0. 05)。观察组LVEF、6 min步行距离、明尼苏达心力衰竭生命质量量表(MLHFQ)均显著高于对照组,差异有统计学意义(P 0. 05)。2组不良事件总发生率比较,差异无统计学意义(P 0. 05),但对照组4例患者出现血清肌酐、尿素氮水平异常,发生率高于观察组,差异有统计学意义(P 0. 05)。经1年随访,观察组心血管事件人均发生次数显著少于对照组(P 0. 05),但2组住院次数和全因死亡率比较,差异无统计学意义(P 0. 05)。结论:健脾生血片可有效治疗心力衰竭伴贫血,减少心血管发生次数,并且安全性良好,其作用机制与提供准确足量铁元素、抑制铁调素表达,抑制慢性炎性反应有关。 相似文献
3.
目的:探究金水宝片联合依诺肝素对维持性血液透析患者血脂代谢的影响。方法:选取2018年12月至2019年3月马鞍山十七冶医院血液净化中心进行透析的患者154例作为研究对象,根据用药不同分为对照组和观察组,每组77例。对照组常规应用依诺肝素抗凝,观察组在对照组抗凝基础上加用金水宝片,各组均干预3个月,比较2组患者血脂变化及持续血液透析并发症发生情况。结果:治疗后,观察组患者三酰甘油、总胆固醇及低密度脂蛋白胆固醇水平下降,高密度脂蛋白胆固醇升高,与治疗前比较差异均有统计学意义(P<0.05),与对照组治疗后比较,差异有统计学意义(P<0.05);观察组总并发症发生率明显低于对照组,2组比较差异有统计学意义(P<0.05);2组患者维持性血液透析不良反应发生率均较低,组间比较差异无统计学意义(P>0.05)。结论:金水宝片联合依诺肝素有助于改善维持性血液透析患者血脂代谢水平,降低维持性血液透析相关并发症,值得临床推广应用。 相似文献
4.
黄平 《浙江中医药大学学报》2004,28(4):24-26
目的:观察中药降糖益肾方合二甲双胍片治疗2型糖尿病的临床疗效.方法:治疗组50例口服降糖益肾方、二甲双胍片.对照组45例口服二甲双胍片.两组均连续用药3个月,监测两组治疗前后空腹及餐后2h血糖(FPG、PG2h)、空腹胰岛素(Fins)血脂(TC、TG)及血液流变学指标变化,并计算胰岛素敏感指数(IAI).结果:治疗组临床症状改善、FPG、PG2h、Fins、TC、TG以及血浆粘比度、红细胞压积、纤维蛋白原与对照组比较明显降低,IAI明显提高(P<0.01、P<0.05).结论:中药降糖益肾方合二甲双胍片治疗2型糖尿病疗效确切. 相似文献
5.
J. Åberg B. Abrahamsson M. Grind G. Nyberg B. Olofsson 《European journal of clinical pharmacology》1997,52(6):471-477
Objective: The primary aim of this study was to investigate whether bioequivalence is achieved for a new fixed combination of extended-release
(ER) felodipine and controlled-release (CR/ZOK) metoprolol␣compared with the free combination of felodipine ER metoprolol
CR/ZOK. The second aim was to study whether there was an interaction in pharmacokinetics and pharmacodynamics between felodipine
and metoprolol when administered as ER formulation.
Methods: Two four-way cross-over studies were performed in 36 young subjects and 24 elderly subjects with frequent measurement of
drug plasma concentrations, blood pressures and heart rate. The pharmacokinetic analysis included enantioselective analysis
in six subjects.
Results: Bioequivalence between the fixed combination and the free combination was observed for the two drugs (mean difference 27%)
except for a minor deviation regarding Cmax of metoprolol in the elderly. No significant interaction was shown except for a small increase (6%) of metoprolol AUC in
the younger subjects. Mean plasma S-/R-enantiomer ratios were almost identical for the different treatments. Blood pressure and heart rate was significantly reduced
for the fixed combination compared with felodipine ER in the younger and the elderly subjects. No significant difference regarding
pharmacodynamics was detected between the fixed combination and the corresponding free combination.
Conclusion: The fixed combination consistently provides fairly constant and effective felodipine and metoprolol concentrations after
once-daily administration of one tablet. It is clinically interchangeable with the free combination of metoprolol CR/ZOK tablets
and felodipine ER tablets. Finally, felodipine and metoprolol do not interact on a pharmacokinetic level when administered
as the fixed combination.
Received: 29 October 1996 / Accepted in revised form: 21 March 1997 相似文献
6.
脑络康缓释胶囊的制备工艺和体外释放度的研究 总被引:4,自引:0,他引:4
以羟丙甲基纤维素作为主要的缓释辅料,采用正交设计方法优化处方研制成脑络康缓释胶囊.以人参皂苷的累积释放量作为考察指标,按照<药典>规定的缓释制剂的释放度进行优选.结果:最佳的处方工艺即羟丙甲基纤维素216 mg,乙基纤维素24 mg,混合稀释剂132 mg,释放曲线符合Higuchi动力学模型. 相似文献
7.
In rabbit platelet rich plasma (PRP), 5-hydroxytraptamine (5-HT,0.03~3μmol/L) induced decrease in light transmission (DLT) dose-de pendently with centralization, as revealed by electron microscopy. However, 5-HT did not induced platelet aggregation and release reaction. 5-HT-induced DLT was inhibited by methysergide (0.3~30μmol/L), indomethacin (0.3~10μmol/L) and PGE_1 (0.01~0.3μmol/L) in a dose-dependent manner, but not EGTA(0.3~3mmol/L). Collagen(Coll), arachidonic acid (AA), adenosine diphosphate (ADP) and a stable thromboxane A2 analoge(STA_2) also induced DLT before aggregation by themselves, which was also inhibited by PGE_1, but not inhibited by EGTA except for Coll However,Coll-, AA-, STA_2-and ADP-induced DLT were reduced by pretreatment of PRP with 5-HT dose-depen-dently. The duration of DLT by Coll and AA were decreased from 151.4±5.93 sec and 15(?)38±0.60sec to 45.44±4.04 sec and 9.00±1.25 sec respectively ((?)±s(?) P<0.01), but not by ADP and STA_2, 3μmol/L of ADP-and 0.3μmol/L of STA_2-induced aggregation which was not accompanied with release reaction were enhanced by 5-HT pretreatment, but in those (Coil 5μg/ml, AA 100~200μmol/L and STA_2 1~3 μmol/L) with release reaction, the amount of adenosine triphosphate(ATP)were suppressed significantly (P<0.001) by 5-HT pretreatment without the effect on the magnitude of aggregation, The mobilization of cytosolic free calcium concentration ([Ca~(2+)]i) was observed after 5-HT treatment in single washed platelet, the results indicated that the basic level of [Ca~(2+)] i was 64.78±3.24nmol/L and this level was increased dose-dependently and significantly at 30 sec after administration of 5-HT and the time of peak value of [Ca~(2+)] i was at 90~100 sec.The similar time courses of suppression of ATP released during aggregation, in cases of Coll(5μg/ml), AA (200μmol/L) and STA_2(3μmol/L), by 5-HT were also found in the present experiment. 相似文献
8.
妇科恶性肿瘤术后骨质疏松症的防治 总被引:1,自引:0,他引:1
为探讨妇科恶性肿瘤术后骨质疏松症的预防措施,采用补充紫竹爱维和乐力胶囊来预防骨质疏松的发生,分别与未服药的妇科恶性肿瘤及良性肿瘤术后作对照,并对其对骨代谢指标血清骨性碱性磷酸酶(BALP)及血清抗酒石酸酸性磷酸酶(TRAP)的影响进行了临床观察.结果发现恶性肿瘤术后较良性肿瘤术后患者的BALP降低,TRAP增高,服用紫竹爱维与乐力胶囊的患者TRAP均低于未服药的恶性肿瘤术后患者,P<0.05,均有显著性差异.表明妇科恶性肿瘤术后患者较良性肿瘤更易患骨质疏松症,服用紫竹爱维与乐力胶囊均能有效防治骨质疏松症,前者效果更佳,但应掌握性激素补充治疗(HRT)的应用指征. 相似文献
9.
INTRODUCTION Under physiological conditions, interferon-α (IFN-α) is a key cytokine produced by virtually all cells in the mammalian organism in response to a variety of bacterial and viral stimuli. In response to viral infection, IFN-α produced by the infected target cells induces a number of cellular genes involved in inhibition of viral replication. In addition, IFN-α is secreted by stimulated NK-cells and T-cells and exerts a multitude of immune stimulatory effects of innate a… 相似文献
10.
Vincenzo Arizza Nicol Parrinello Sandra Schimmenti 《Developmental and comparative immunology》1991,15(4):219-226
-Lactose specific lectins are released from Phallusia mamillata hemocytes during short-term cultures. The molecular weight of the subunits, the immunological cross-reaction and the sugar specificity suggest that the released lectins are similar to those isolated from the sonicated hemocytes. Because lectin release appears to take place independently of active protein synthesis, the possibility exists that lectins are pre-formed, stored in hemocytes and released when in vitro conditions stimulate the cells. 相似文献